News & Views - Page 30 of 53 - Telix Pharmaceuticals Limited

First Patient Enrolled in ProstACT TARGET Study

Telix and GenesisCare, the largest provider of integrated cancer care in Australia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix’s prostate cancer antibody therapy candidate TLX591 (177Lu-DOTA-rosopatamab), in patients experiencing a first recurrence of prostate-specific antigen (PSA) after initial therapy for prostate cancer.

Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data

Telix today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[ ¹³¹I] iodo-phenylalanine, or ¹³¹I-IPA) in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma multiforme (GBM).

Telix at AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24 2022.

Telix Japan – Telix Luncheon Seminar at WFNMB 2022

We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center from September 7-11 2022.

Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment

Telix and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.

Telix Half-Year Results 2022 and Shareholder Update

Telix is pleased to present the Company’s financial results for the half-year ending 30 June 2022, together with a shareholder update.

Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant

Telix today announces that it has been jointly awarded a $4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part of a consortium of applicants led by The University of Queensland (UQ).

Telix 1H 2022 Financial Results and Company Update Investor Call

Telix advises that it will release financial results for the half-year ending 30 June 2022 on Thursday 18 August 2022.

APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

Telix today reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific (APAC) Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited (Grand Pharma).

BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging

Telix and BAMF Health use Illuccix® for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging